GO:0071813 lipoprotein particle binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0071813 (lipoprotein particle binding) is a molecular function defined as binding to a lipoprotein particle, a non-covalent lipid-protein clathrate with a hydrophilic surface.
• Lipoprotein particles are central to lipid transport, and their binding underlies cholesterol trafficking, atherogenesis, and extracellular vesicle interactions [1,2,8].
• Key proteins involved include apolipoproteins (APOA1, APOB, APOE), receptors (LDLR, SCARB1), and lipid transfer proteins (CETP, PLTP) [1,2].
• Dysregulation of lipoprotein particle binding is linked to cardiovascular disease, neurodegeneration, and cancer.
• Experimental models such as knockout, knock-in, and overexpression cell lines are essential to dissect binding mechanisms [1,2].
• CRISPR-based screens and bioinformatics can identify novel regulators of lipoprotein particle binding [1,2].
Description
Lipoprotein particle binding (GO:0071813) is a molecular function that mediates the interaction of proteins with lipoprotein particles, which are complex assemblies of lipids and proteins. These particles are essential for the transport of cholesterol, triglycerides, and other lipids in the bloodstream and within cells. The binding event is critical for lipid uptake, signaling, and metabolism, and its dysregulation contributes to diseases such as atherosclerosis and neurodegeneration. Understanding the molecular players and mechanisms of lipoprotein particle binding is therefore of broad biomedical importance. This article integrates the QuickGO definition with published literature to provide a comprehensive overview of the term, its associated genes, and research methodologies [1,2,8].
lipoprotein particle binding At A Glance
| GO ID | GO:0071813 |
|---|---|
| GO term | lipoprotein particle binding |
| Ontology | molecular_function |
| Synonym | lipoprotein binding, plasma lipoprotein binding, plasma lipoprotein particle binding |
| Major function | Binding to lipoprotein particles, facilitating lipid transport and metabolism |
| Definition source | QuickGO |
| Related cellular component | lipoprotein particle (GO:1990777) |
| Related biological process | lipid transport (GO:0006869) |
What Is GO:0071813?
According to the Gene Ontology, lipoprotein particle binding (GO:0071813) is the binding to a lipoprotein particle. A lipoprotein particle, also known as a lipoprotein, is a clathrate complex consisting of a lipid enwrapped in a protein host without covalent binding in such a way that the complex has a hydrophilic outer surface consisting of all the protein and the polar ends of any phospholipids. This definition highlights the non-covalent, dynamic nature of the interaction and the amphipathic structure of lipoprotein particles.
Why Is lipoprotein particle binding Important in Cell Biology?
Lipoprotein particle binding is fundamental to lipid homeostasis and is implicated in a wide range of physiological and pathological processes [1,2]. It governs the clearance of lipoproteins from circulation, the delivery of lipids to tissues, and the initiation of signaling cascades [1,2]. Dysregulation of this binding is a hallmark of atherosclerosis, where apolipoprotein B-containing lipoproteins accumulate and trigger inflammation. Moreover, emerging evidence links lipoprotein particle binding to extracellular vesicle interactions, expanding its role in intercellular communication. Thus, studying this function is crucial for understanding metabolic diseases and developing therapeutic interventions [1,2].
• Critical for cholesterol transport and cellular lipid uptake.
• Central to the pathogenesis of atherosclerosis and cardiovascular disease.
• Involved in neurodegenerative disorders through apolipoprotein E interactions.
• Modulates immune responses via lipoprotein-immune cell crosstalk.
• Emerging role in extracellular vesicle biology and intercellular communication.
• Target for lipid-lowering therapies and drug development.
• Essential for understanding metabolic syndrome and diabetes.
• Provides insights into membrane biogenesis and lipid droplet formation.
• Key to studying host-pathogen interactions via bacterial lipoprotein binding [5,7].
• Enables development of diagnostic biomarkers for lipid disorders.
What Happens During lipoprotein particle binding?
Recognition and Initial Contact
In simple terms: The binding protein first recognizes and attaches to the lipoprotein particle.
The initial step involves the recognition of specific apolipoproteins or lipid moieties on the lipoprotein particle by binding proteins such as receptors or lipid transfer proteins. For example, apolipoprotein B (APOB) on low-density lipoprotein (LDL) is recognized by the LDL receptor (LDLR), leading to high-affinity binding. This interaction is mediated by electrostatic and hydrophobic forces, as the lipoprotein particle presents a hydrophilic surface composed of protein and phospholipid polar heads.
Conformational Changes and Stabilization
In simple terms: After binding, the proteins change shape to lock onto the particle.
Upon initial contact, binding proteins undergo conformational changes that stabilize the complex. For instance, the binding of apolipoprotein A-I (APOA1) to lipids induces a conformational shift from random coil to alpha-helix, facilitating stable lipoprotein particle binding. This step is critical for subsequent lipid transfer or cellular uptake.
Lipid Transfer and Cellular Uptake
In simple terms: The bound particle can then transfer lipids or be taken into cells.
Following stable binding, lipoprotein particles can donate or accept lipids via transfer proteins such as cholesteryl ester transfer protein (CETP) or phospholipid transfer protein (PLTP). Alternatively, the entire particle can be internalized through receptor-mediated endocytosis, as seen with LDLR. This process is essential for delivering cholesterol to cells and maintaining lipid homeostasis.
Intracellular Trafficking and Metabolism
In simple terms: Inside the cell, the particle is processed and its components are recycled or degraded.
After uptake, lipoprotein particles are trafficked to endosomes and lysosomes, where they are hydrolyzed to release cholesterol and fatty acids. Intracellular cholesterol trafficking is tightly regulated by proteins such as NPC1 and NPC2. Defects in this pathway lead to cholesterol accumulation and disease.
Extracellular Vesicle Interactions
In simple terms: Lipoproteins can also bind to extracellular vesicles, affecting their function.
Recent studies have uncovered binding between lipoproteins and extracellular vesicles, which can modulate vesicle cargo and cellular targeting. This interaction is mediated by specific lipid and protein components and may have implications for intercellular communication and disease.
Key Genes Involved in GO:0071813 lipoprotein particle binding
The following genes encode proteins that directly or indirectly participate in lipoprotein particle binding, as supported by published literature [1,2,8].
| Gene | Major Role | Research Relevance |
|---|---|---|
| APOA1 | Major apolipoprotein of HDL; binds lipids to form HDL particles | Studied for reverse cholesterol transport and atherosclerosis |
| APOB | Core apolipoprotein of LDL and VLDL; ligand for LDLR | Central to atherogenesis and lipid metabolism |
| APOE | Apolipoprotein involved in lipid transport and neuronal repair | Linked to Alzheimer's disease and cardiovascular risk |
| LDLR | Cell surface receptor that binds APOB and APOE on lipoproteins | Mutations cause familial hypercholesterolemia |
| SCARB1 | Scavenger receptor class B member 1; binds HDL | Mediates selective cholesterol uptake |
| CETP | Cholesteryl ester transfer protein; transfers lipids between lipoproteins | Target for lipid-modifying drugs |
| PLTP | Phospholipid transfer protein; transfers phospholipids between lipoproteins | Involved in HDL remodeling |
| LPL | Lipoprotein lipase; hydrolyzes triglycerides in lipoproteins | Regulates energy homeostasis |
| LCAT | Lecithin-cholesterol acyltransferase; esterifies cholesterol on HDL | Deficiency causes fish-eye disease |
| NPC1 | Niemann-Pick C1; mediates intracellular cholesterol trafficking | Mutations cause Niemann-Pick disease type C |
| NPC2 | Niemann-Pick C2; binds cholesterol in lysosomes | Deficiency leads to cholesterol accumulation |
| ABCA1 | ATP-binding cassette transporter A1; lipidates APOA1 | Mutations cause Tangier disease |
| ABCG1 | ATP-binding cassette transporter G1; effluxes cholesterol to HDL | Regulates macrophage cholesterol efflux |
| SR-BI | Scavenger receptor BI; binds HDL and mediates selective uptake | Role in steroidogenesis and atherosclerosis |
| PCSK9 | Proprotein convertase subtilisin/kexin type 9; regulates LDLR degradation | Target for cholesterol-lowering therapies |
| Lp(a) | Lipoprotein(a); binds oxidized phospholipids | Risk factor for cardiovascular disease |
| tBid | Proapoptotic Bcl-2 family protein; forms lipoprotein particles | Studied in apoptosis and lipid dynamics |
How Is lipoprotein particle binding Regulated?
Lipoprotein particle binding is regulated at multiple levels, including transcriptional control of receptor and apolipoprotein genes, post-translational modifications, and feedback mechanisms [1,2]. For instance, intracellular cholesterol levels regulate the expression of LDLR via the SREBP pathway. Additionally, PCSK9 modulates LDLR availability by promoting its degradation. Lipid transfer proteins such as CETP and PLTP are regulated by metabolic and inflammatory signals. Emerging evidence suggests that extracellular vesicles can also influence lipoprotein binding.
lipoprotein particle binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| APOB | Atherosclerosis, familial hypercholesterolemia | Knockout and knock-in cell lines |
| APOE | Alzheimer's disease, cardiovascular disease | Point mutation knock-in (APOE4) |
| LDLR | Familial hypercholesterolemia | Knockout and overexpression |
| SCARB1 | Cancer, lipid metabolism disorders | Knockout and tagged knock-in |
| NPC1 | Niemann-Pick disease type C | Knockout and point mutation |
Atherosclerosis and Cardiovascular Disease
Atherosclerosis is driven by the retention and modification of apolipoprotein B-containing lipoproteins in the arterial wall. Binding of these lipoproteins to proteoglycans and subsequent uptake by macrophages leads to foam cell formation and plaque development. Genetic variants in APOB, LDLR, and PCSK9 affect lipoprotein binding and are associated with cardiovascular risk.
Neurodegeneration
Apolipoprotein E (APOE) isoforms differentially bind to lipoprotein particles and influence amyloid-beta clearance in Alzheimer's disease. The APOE4 isoform is a major genetic risk factor for late-onset Alzheimer's disease, partly due to altered lipid binding and transport.
Cancer
Lipoprotein particle binding can affect cancer cell proliferation by modulating lipid availability. For example, scavenger receptor BI (SCARB1) mediates HDL uptake and is overexpressed in some cancers, supporting rapid growth.
From lipoprotein particle binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X directly bind lipoprotein particles? | Knockout cell line followed by binding assays |
| What is the effect of a disease-associated point mutation on binding affinity? | Point mutation knock-in cell line |
| Can a tagged version of the protein be used to track binding dynamics? | Tagged knock-in (e.g., GFP) |
| Does overexpression of gene Y enhance lipoprotein uptake? | Overexpression cell line |
| Which genes regulate lipoprotein particle binding in a genome-wide manner? | CRISPR library screening |
| How does a specific mutation affect downstream lipid trafficking? | Knock-in and bioinformatics analysis |
How to Study the lipoprotein particle binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ELISA | Binding affinity between protein and lipoprotein | Quantitative binding studies |
| Surface plasmon resonance | Real-time binding kinetics | Interaction analysis |
| Western blot | Protein expression and modification | Validation of binding partners |
| Single-particle imaging | Visualization of lipoprotein-vesicle binding | Nanoscale interaction studies |
| CRISPR screen | Genes regulating binding | Functional genomics |
| RNA-seq | Transcriptional changes upon binding | Pathway analysis |
| Proteomics | Protein composition of lipoprotein particles | Biomarker discovery |
| Lipidomics | Lipid species in particles | Metabolic profiling |
Binding Assays
Direct binding assays such as enzyme-linked immunosorbent assay (ELISA) or surface plasmon resonance (SPR) can measure the affinity between proteins and lipoprotein particles. These methods are quantitative and can be adapted for high-throughput screening.
Western Blotting
Western blotting is used to detect and quantify specific proteins in lipoprotein fractions or after binding assays. It allows assessment of protein expression and post-translational modifications.
Imaging and Single-Particle Analysis
Advanced imaging techniques, including single-particle analysis, can visualize lipoprotein-extracellular vesicle binding and quantify interactions at the nanoscale. These methods provide insights into binding stoichiometry and dynamics.
CRISPR Screening and Bioinformatics
Genome-wide CRISPR knockout or activation screens can identify genes that regulate lipoprotein particle binding. Bioinformatics tools then analyze the data to pinpoint pathways and networks.
How CRISPR Can Be Used to Study GO:0071813 lipoprotein particle binding
Knockout
CRISPR knockout of candidate genes (e.g., LDLR, SCARB1) in cell lines can abolish lipoprotein particle binding, providing causal evidence. Such models are used to study lipid uptake and metabolism.
Point Mutation
Introducing disease-associated point mutations (e.g., in APOB or APOE) via CRISPR allows assessment of their impact on binding affinity and downstream effects. This is crucial for understanding genetic risk factors.
Knock-in
Knock-in of tagged versions of genes (e.g., GFP-APOA1) enables live-cell imaging and tracking of lipoprotein particle binding. This approach provides dynamic insights into binding and trafficking.
Overexpression
Overexpression of genes such as SCARB1 or ABCA1 can enhance lipoprotein particle binding and lipid efflux, respectively. These models are used to study gain-of-function effects and potential therapeutic targets.
How EDITGENE Supports lipoprotein particle binding Research
Researchers studying lipoprotein particle binding-related genes often need to determine whether a candidate gene is causally involved in binding, lipid transport, or disease pathogenesis. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional studies.
Contact EDITGENE today to design your custom CRISPR model for lipoprotein particle binding research.
Frequently Asked Questions About lipoprotein particle binding
What is lipoprotein particle binding?
Lipoprotein particle binding (GO:0071813) is the molecular function of binding to a lipoprotein particle, a non-covalent complex of lipids and proteins with a hydrophilic surface.
What genes are involved in lipoprotein particle binding?
Key genes include APOA1, APOB, APOE, LDLR, SCARB1, CETP, PLTP, and NPC1, among others [1,2].
How is lipoprotein particle binding studied?
Common methods include binding assays (ELISA, SPR), western blotting, imaging, and CRISPR screens [1,6,8].
What diseases are associated with defective lipoprotein particle binding?
Atherosclerosis, Alzheimer's disease, and certain cancers are linked to dysregulation of lipoprotein particle binding [1,2].
What is the GO definition of lipoprotein particle binding?
The GO definition is binding to a lipoprotein particle, a clathrate complex of lipid enwrapped in protein with a hydrophilic outer surface.
Can CRISPR be used to study lipoprotein particle binding?
Yes, CRISPR knockout, knock-in, and overexpression models are powerful tools to dissect the function of genes involved in lipoprotein particle binding [1,2].
What are the synonyms for lipoprotein particle binding?
Synonyms include lipoprotein binding, plasma lipoprotein binding, and plasma lipoprotein particle binding.
Which apolipoproteins are most studied in lipoprotein particle binding?
APOA1, APOB, and APOE are extensively studied due to their roles in HDL, LDL, and neuronal lipid transport [1,2].
How does lipoprotein particle binding relate to extracellular vesicles?
Recent research shows that lipoproteins can bind to extracellular vesicles, influencing vesicle cargo and cellular communication.
What model systems are available for lipoprotein particle binding research?
Knockout, point mutation knock-in, tagged knock-in, and overexpression cell lines are commonly used, along with CRISPR screens [1,2].
Conclusion
Lipoprotein particle binding (GO:0071813) is a fundamental molecular function with far-reaching implications for lipid metabolism, cardiovascular health, and neurodegeneration [1,2]. Advances in CRISPR-based models and high-throughput screening are accelerating the discovery of new players and mechanisms [1,8]. EDITGENE's comprehensive services empower researchers to generate precise cell models and uncover causal relationships, driving therapeutic innovation in lipid-related diseases [1,2].
References
- 1. Ikonen E et al.. 2023. Intracellular Cholesterol Trafficking.. Cold Spring Harb Perspect Biol 15(8) PMID: 37277190
- 2. Borén J et al.. 2025. Apolipoprotein B-containing lipoproteins in atherogenesis.. Nat Rev Cardiol 22(6):399-413 PMID: 39743565
- 3. Ekanayake V et al.. 2018. Lipoprotein Particle Formation by Proapoptotic tBid.. Biophys J 115(3):533-542 PMID: 30017071
- 5. Shlosman I et al.. 2025. The hit-and-run of cell wall synthesis: LpoB transiently binds and activates PBP1b through a conserved allosteric switch.. Nat Commun 16(1):6723 PMID: 40691462
- 6. Freeman LA. 2013. Western blots.. Methods Mol Biol 1027:369-85 PMID: 23912997
- 7. Chen H et al.. 2025. Structural basis of lipopolysaccharide assembly by the outer membrane translocon holo-complex.. Nat Commun 16(1):10404 PMID: 41285762
- 8. Musicò A et al.. 2026. Orthogonal Investigation at Single-Particle and Ensemble Levels Uncovers Lipoprotein-Extracellular Vesicle Binding.. Anal Chem 98(2):1390-1405 PMID: 41502393
